Changchun Genescience Pharmaceuticals identifies new FGFR2/3 inhibitors

June 12, 2026

Changchun Genescience Pharmaceuticals Co. Ltd. has discovered salts of fibroblast growth factor receptor 2 (FGFR2) and/or fibroblast growth factor receptor 3 (FGFR3) inhibitors reported to be useful for diagnosis and treatment of cancer, achondroplasia and osteochondrodysplasia.

BioWorld Science Cancer Patents

Today's news in brief

BioWorld

BioWorld briefs for June 12, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 9, 2026

3D rendering of β2-Adrenergic receptor GPCR protein molecule embedded in lipid bilayer membrane.

Skape Bio unlocks GPCR targets with de novo-designed miniproteins

BioWorld

Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...

Pre-disease plasma signature may help redefine lung cancer risk

BioWorld

Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...

New 5-HT2C receptor agonists reported in Hansoh patent

BioWorld Science

Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed tricyclic compounds acting as 5-HT2C receptor...